Literature DB >> 24390364

SCUBE3 overexpression predicts poor prognosis in non-small cell lung cancer.

Chao Zhao1, Qin qin, Qianqian Wang, Jianrong Zhang, Yulian Xu, Wenjie Li, Mingli Gu, Sunxiao Chen, Anmei Deng.   

Abstract

Signal peptide-CUB-EGF-like domain-containing protein 3 (SCUBE3) is highly expressed in invasive lung cancers. In vitro investigation indicated that SCUBE3 may play a critical role in lung cancer invasion and metastasis. The current study immunohistochemically investigated the expression of SCUBE3 in 119 cases of non-small cell lung cancer (NSCLC) tumors and this study evaluated its clinical-pathological and prognostic significance. SCUBE3 was found to be up-regulated in NSCLC tissue samples compared to adjacent normal tissue. High SCUBE3 expression was noted in 84/119 (70.6%) of NSCLC tissue samples and was positively correlated with lymph node involvement (p = 0.001) and advanced stages of tumor/lymph node metastasis (TNM) (p = 0.014). Furthermore, high SCUBE3 expression was significantly associated with loss of the epithelial marker E-cadherin (p = 0.0015) and acquisition of expression of the mesenchymal marker vimentin (p = 0.005). Patients with high SCUBE3 expression had significantly a shorter survival time compared to patients with low SCUBE3 expression (p = 0.001), and SCUBE3 expression served as an independent prognostic factor for NSCLC patients. Results indicated that SCUBE3 might be involved in regulating the epithelial-mesenchymal transition (EMT) and malignant progression in NSCLC. Results also indicated that SCUBE3d may be a potential therapeutic target for lung cancers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24390364

Source DB:  PubMed          Journal:  Biosci Trends        ISSN: 1881-7815            Impact factor:   2.400


  9 in total

1.  Prognostic and clinicopathological significance of downregulated E-cadherin expression in patients with non-small cell lung cancer (NSCLC): a meta-analysis.

Authors:  Yan-Long Yang; Ming-Wu Chen; Lei Xian
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

2.  The First Scube3 Mutant Mouse Line with Pleiotropic Phenotypic Alterations.

Authors:  Helmut Fuchs; Sibylle Sabrautzki; Gerhard K H Przemeck; Stefanie Leuchtenberger; Bettina Lorenz-Depiereux; Lore Becker; Birgit Rathkolb; Marion Horsch; Lillian Garrett; Manuela A Östereicher; Wolfgang Hans; Koichiro Abe; Nobuho Sagawa; Jan Rozman; Ingrid L Vargas-Panesso; Michael Sandholzer; Thomas S Lisse; Thure Adler; Juan Antonio Aguilar-Pimentel; Julia Calzada-Wack; Nicole Ehrhard; Ralf Elvert; Christine Gau; Sabine M Hölter; Katja Micklich; Kristin Moreth; Cornelia Prehn; Oliver Puk; Ildiko Racz; Claudia Stoeger; Alexandra Vernaleken; Dian Michel; Susanne Diener; Thomas Wieland; Jerzy Adamski; Raffi Bekeredjian; Dirk H Busch; John Favor; Jochen Graw; Martin Klingenspor; Christoph Lengger; Holger Maier; Frauke Neff; Markus Ollert; Tobias Stoeger; Ali Önder Yildirim; Tim M Strom; Andreas Zimmer; Eckhard Wolf; Wolfgang Wurst; Thomas Klopstock; Johannes Beckers; Valerie Gailus-Durner; Martin Hrabé de Angelis
Journal:  G3 (Bethesda)       Date:  2016-12-07       Impact factor: 3.154

3.  Clinicopathological significance and prognostic value of E-cadherin expression in non-small cell lung cancer: A protocol for systematic review and meta-analysis.

Authors:  Dong Chao; Gawei Hu; Qingxin Li
Journal:  Medicine (Baltimore)       Date:  2021-02-19       Impact factor: 1.817

4.  SCUBE3 serves as an independent poor prognostic factor in breast cancer.

Authors:  Qin Huo; Xi He; Zhenwei Li; Fan Yang; Shengnan He; Ling Shao; Ye Hu; Siqi Chen; Ni Xie
Journal:  Cancer Cell Int       Date:  2021-05-18       Impact factor: 5.722

5.  DEPDC1B Promotes Melanoma Angiogenesis and Metastasis through Sequestration of Ubiquitin Ligase CDC16 to Stabilize Secreted SCUBE3.

Authors:  Feng Hu; Ki On Fong; May Pui Lai Cheung; Jessica Aijia Liu; Rui Liang; Tsz Wai Li; Rakesh Sharma; Philip Pun-Ching Ip; Xintao Yang; Martin Cheung
Journal:  Adv Sci (Weinh)       Date:  2022-01-27       Impact factor: 16.806

6.  Prognostic Values of Vimentin Expression and Its Clinicopathological Significance in Non-Small Cell Lung Cancer: A Meta-Analysis of Observational Studies with 4118 Cases.

Authors:  Zhihua Ye; Xin Zhang; Yihuan Luo; Shikang Li; Lanshan Huang; Zuyun Li; Ping Li; Gang Chen
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

7.  Reduction of SCUBE3 by a new marine-derived asterosaponin leads to arrest of glioma cells in G1/S.

Authors:  Peng-Cheng Qiu; Yun-Yang Lu; Shan Zhang; Hua Li; Han Bao; Yu-Qiang Ji; Fei Fang; Hai-Feng Tang; Guang Cheng
Journal:  Oncogenesis       Date:  2020-08-06       Impact factor: 7.485

8.  Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model.

Authors:  Michelle Zalles; Nataliya Smith; Jadith Ziegler; Debra Saunders; Shannon Remerowski; Lincy Thomas; Rafal Gulej; Nadya Mamedova; Megan Lerner; Kar-Ming Fung; Junho Chung; Kyusang Hwang; Junyeong Jin; Graham Wiley; Chase Brown; James Battiste; Jonathan D Wren; Rheal A Towner
Journal:  J Cell Mol Med       Date:  2019-12-21       Impact factor: 5.310

9.  Integrated Analysis of Competing Endogenous RNAs Network Reveals Potential Signatures in Osteosarcoma Development.

Authors:  Lisong Heng; Zhen Jia; Jian Sun; Yitong Zhao; Kun Zhang; Yangjun Zhu; Shemin Lu
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.